Cyclopharm

BUY
Date of inclusion: 16 April 2021
Share price on inclusion in Marc & Stuart's Top Picks: $2.55
52-week range: A$1.16 / A$3.45
Risk Level: High

 

The gold standard in diagnostic functional lung imaging technology

Cyclopharm is a supplier of radiopharmaceuticals, that is, radioisotopes used in medical diagnosis. Its core product is Technegas, which is an ultra-fine dispersion of Technetium-labelled carbon. Technegas is inhaled by a patient to allow easy diagnosis of pulmon...

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks